<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001058</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 223</org_study_id>
    <secondary_id>11200</secondary_id>
    <nct_id>NCT00001058</nct_id>
  </id_info>
  <brief_title>A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS</brief_title>
  <official_title>A Phase II/III Prospective, Multicenter, Randomized, Controlled Trial Comparing the Safety and Efficacy of Three Clarithromycin-Containing Combination Drug Regimens for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Disease in Persons With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of clarithromycin combined with rifabutin, ethambutol, or&#xD;
      both in the treatment of disseminated Mycobacterium avium Complex (MAC) disease in persons&#xD;
      with AIDS, including individuals who have or have not received prior MAC prophylaxis.&#xD;
&#xD;
      It is believed that effective therapy for MAC disease in patients with AIDS requires&#xD;
      combinations of two or more antimycobacterial agents in order to overcome drug resistance and&#xD;
      the unfavorable influence of the profound immunosuppression associated with AIDS. Data&#xD;
      suggest that clarithromycin may have substantial activity in two- or three-drug combination&#xD;
      regimens with clofazimine, rifamycin derivatives, ethambutol, or the 4-quinolones.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is believed that effective therapy for MAC disease in patients with AIDS requires&#xD;
      combinations of two or more antimycobacterial agents in order to overcome drug resistance and&#xD;
      the unfavorable influence of the profound immunosuppression associated with AIDS. Data&#xD;
      suggest that clarithromycin may have substantial activity in two- or three-drug combination&#xD;
      regimens with clofazimine, rifamycin derivatives, ethambutol, or the 4-quinolones.&#xD;
&#xD;
      Patients are randomized to one of three treatment arms containing clarithromycin in&#xD;
      combination with ethambutol, rifabutin, or both. Clarithromycin alone is taken on days 1&#xD;
      through 3 to determine tolerance and rifabutin and/or ethambutol is added on day 3. AS PER&#xD;
      AMENDMENT 7/2/97: Patients may elect to add ritonavir or indinavir to their treatment&#xD;
      regimen. Treatment continues daily for 48 weeks. In the absence of a dose-limiting toxicity,&#xD;
      those patients who are determined to be complete or partial responders continue on the&#xD;
      regimen to which they were originally assigned. Patients who have failed or relapsed on&#xD;
      originally assigned MAC therapy, must have their therapy amended to receive clarithromycin&#xD;
      and at least two other drugs not included in their originally assigned regimen. Patients are&#xD;
      followed twice in the first week, then every 2 weeks for the first 2 months, then monthly for&#xD;
      the next 4 months, and then every 2 months thereafter until the end of 12 months. PER&#xD;
      AMENDMENT 10/10/96: NOTE: Any patient who develops a toxicity to rifabutin or ethambutol&#xD;
      after week 12 or thereafter will be offered the option of being registered to a salvage&#xD;
      regimen of 2 new drugs not previously received, plus clarithromycin to continue for the study&#xD;
      duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">January 1999</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>246</enrollment>
  <condition>Mycobacterium Avium-intracellulare Infection</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral therapy.&#xD;
&#xD;
          -  Maintenance or prophylactic therapy for other opportunistic infections (with the&#xD;
             exception of specifically excluded drugs).&#xD;
&#xD;
          -  Carbamazepine or theophylline.&#xD;
&#xD;
          -  Isoniazid for TB prophylaxis.&#xD;
&#xD;
        PER AMENDMENT 10/10/96:&#xD;
&#xD;
          -  Therapy for acute infectious processes, other than MAC, provided that the patient is&#xD;
             stable on the therapy.&#xD;
&#xD;
          -  Fluconazole therapy for maintenance or suppression of fungal infections, providing the&#xD;
             patient has been on a stable dose for at least 4 weeks.&#xD;
&#xD;
        PER AMENDMENT 7/02/97:&#xD;
&#xD;
          -  If a patient elects to receive indinavir, ORTHO/NOVUM 1/35 is an acceptable means of&#xD;
             birth control.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Disseminated MAC disease.&#xD;
&#xD;
          -  Life expectancy of at least 8 weeks.&#xD;
&#xD;
          -  Consent of parent or guardian if under 18 years of age.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  This protocol is approved for prisoner participation.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        PER AMENDMENT 10/10/96:&#xD;
&#xD;
          -  Therapy for acute infectious processes, other than MAC, prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Active mycobacterial infection other than MAC that requires treatment, with the&#xD;
             exception of isoniazid used solely for TB prophylaxis.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other antimycobacterial drugs (with the exception of isoniazid for TB prophylaxis).&#xD;
&#xD;
          -  Other investigational drugs unless approved by protocol chair.&#xD;
&#xD;
        PER AMENDMENT 7/2/97:&#xD;
&#xD;
          -  For patients who elect to receive indinavir or ritonavir:&#xD;
&#xD;
          -  Terfenadine, astemizole, cisapride, triazolam, or midazolam.&#xD;
&#xD;
          -  For patients who elect to receive ritonavir:&#xD;
&#xD;
          -  alprazolam, amiodarone, bepridil, bupropion, cisapride, clorazepate, clozapine,&#xD;
             diazepam, dihydroergotamine, ergotamine, estazolam, encainide, flecainide, flurazepam,&#xD;
             meperidine, pimozide, piroxicam, propafenone, propoxyphene, quinidine or zolpidem.&#xD;
&#xD;
          -  For patients who elect to receive indinavir:&#xD;
&#xD;
          -  oral contraceptives other than ORTHO/NOVUM as a sole form of birth control.&#xD;
&#xD;
          -  For patients randomized to a rifabutin-containing arm:&#xD;
&#xD;
          -  oral contraceptives or Norplant as a sole form of birth control.&#xD;
&#xD;
        Patients with the following prior condition are excluded:&#xD;
&#xD;
          -  History of severe hypersensitivity to erythromycin, clarithromycin, azithromycin,&#xD;
             ethambutol, rifampin, or rifabutin (including Type 1 hypersensitivity reaction,&#xD;
             Stevens-Johnson syndrome, hepatitis, optic neuritis, or exfoliative dermatitis).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Empiric or presumptive antimycobacterial therapy prior to study entry if &gt; 14 days,&#xD;
             within 90 days prior to entry.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Patients unwilling to discontinue presumptive therapy or empiric therapy may be&#xD;
             enrolled with the permission of the protocol chairs, however, if they are without a&#xD;
             MAC positive blood culture at baseline, they will have study medications discontinued&#xD;
             (AS PER AMENDMENT 7/2/97).&#xD;
&#xD;
        PER AMENDMENT 10/10/96:&#xD;
&#xD;
          -  Treatment with clarithromycin or ethambutol within 4 days of initiation of study&#xD;
             medications.&#xD;
&#xD;
          -  Treatment with rifabutin or rifampin within 7 days of initiation of study medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benson CA</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Chaisson RE</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Currier JS</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd, Avrc Crs</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Med. Ctr. CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Ctr. CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Med. Ctr.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Hawaii at Manoa, Leahi Hosp.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hosp. CORE Ctr.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weiss Memorial Hosp.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Wishard Memorial</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hosp. of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bmc Actg Crs</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess - East Campus A0102 CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Med. Ctr., Div. of Infectious Diseases</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, ACTU</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis ConnectCare, Infectious Diseases Clinic</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr. (Mt. Sinai)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. of the Univ. of Pennsylvania CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mbeya Med. Research Program, Mbeya Referral Hosp. CRS</name>
      <address>
        <city>Mbeya</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Flexner C, Noe D, Benson C, Currier J, Andrade A, Shaver A. Adherence patterns in patients with symptomatic Mycobacterium avium complex (MAC) infection taking a twice-daily clarithromycin regimen. ACTG 223 Study Team. Int Conf AIDS. 1998;12:585 (abstract no 32324)</citation>
  </reference>
  <reference>
    <citation>Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, Inderlied CB, Flexner C, Neidig J, Chaisson R, Notario GF, Hafner R; AIDS Clinical Trials Group 223 Protocol Team. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis. 2003 Nov 1;37(9):1234-43. doi: 10.1086/378807. Epub 2003 Oct 3.</citation>
    <PMID>14557969</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rifabutin</keyword>
  <keyword>Mycobacterium avium-intracellulare Infection</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Ethambutol</keyword>
  <keyword>Clofazimine</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Ciprofloxacin</keyword>
  <keyword>Clarithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

